2nd Quarter - Report

BROWN RUDNICK LLP for APOTEX CORPORATION

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues relating to inter parte review challenges.

LobbyistCovered position, as disclosed
ROBERT DENNIS FOREMAN New The Office of U.S. Senator Orrin Hatch, Senior Health Policy Advisor, (1993 to 2001); Centers for Medicare & Medicaid Services (CMS), Director, Office of Legislation and Congressional Affairs, (2001 to 2005)
LISA LAYMAN SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee(97-99); CBO, PA(92-96)
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2051 - The FAST Generics Act.

LobbyistCovered position, as disclosed
ROBERT DENNIS FOREMAN New The Office of U.S. Senator Orrin Hatch, Senior Health Policy Advisor, (1993 to 2001); Centers for Medicare & Medicaid Services (CMS), Director, Office of Legislation and Congressional Affairs, (2001 to 2005)
LISA LAYMAN SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee(97-99); CBO, PA(92-96)
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2212 (115th), S. 974 (115th), H.R. 2430 (115th), H.R. 2051 (115th), S. 934 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.